TY  - JOUR
AU  - Luis Perez-Gracia, Jose
AU  - Loriot, Yohann
AU  - Rosenberg, Jonathan E.
AU  - Powles, Thomas
AU  - Necchi, Andrea
AU  - Hussain, Syed A.
AU  - Morales-Barrera, Rafael
AU  - Retz, Margitta M.
AU  - Niegisch, Gunter
AU  - Duran, Ignacio
AU  - Theodore, Christine
AU  - Grande, Enrique
AU  - Shen, Xiaodong
AU  - Wang, Jingjing
AU  - Nelson, Betty
AU  - Derleth, Christina L.
AU  - van-der-Heijden, Michiel S.
PY  - 2017
DO  - 10.1016/j.eururo.2017.11.023
SN  - 0302-2838
UR  - http://hdl.handle.net/10668/18776
T2  - European urology
AB  - Background: Patients with metastatic urothelial carcinoma (mUC) who progress after platinum-based chemotherapy have had few treatment options and uniformly poor outcomes. Atezolizumab (anti-programmed death-ligand 1) was approved in the USA for...
LA  - en
PB  - Elsevier BV
KW  - Atezolizumab
KW  - Immunotherapy
KW  - Number of prior regimens
KW  - Previous platinum-based chemotherapy
KW  - Urothelial carcinoma
KW  - Transitional-cell carcinoma
KW  - Long-term-survival
KW  - Bladder-cancer
KW  - Prognostic-factors
KW  - Phase-2 trial
KW  - Single-arm
KW  - Therapy
KW  - Cisplatin
KW  - Chemotherapy
KW  - Methotrexate
KW  - Humans
KW  - Cisplatin
KW  - atezolizumab
KW  - Creatinine
KW  - Platinum
KW  - Ligands
KW  - Response Evaluation Criteria in Solid Tumors
TI  - Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
TY  - research article
VL  - 73
ER  -